Bain Capital Life Sciences Fund II, L.P. 13D and 13G filings for Xilio Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 5:44 pm Purchase |
2024-09-30 | 13G | Xilio Therapeutics, Inc. XLO |
Bain Capital Life Sciences Fund II, L.P. | 4,566,817 11.000% |
3,218,135 (+238.61%) |
Filing |
| 2022-02-14 06:42 am Unchanged |
2021-12-31 | 13G | Xilio Therapeutics, Inc. XLO |
Bain Capital Life Sciences Fund II, L.P. | 1,348,682 4.900% |
0 (Unchanged) |
Filing |
| 2021-11-05 5:16 pm Purchase |
2021-10-26 | 13G | Xilio Therapeutics, Inc. XLO |
Bain Capital Life Sciences Fund II, L.P. | 1,348,682 5.100% |
1,348,682 (New Position) |
Filing |